Ultime notizie per Eli Lilly (NYSE:LLY) Azioni

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Wegovy

Health Care

Hims & Hers Health, Inc. Class A Common Stock

HIMS

I giganti farmaceutici celebrano ricavi record. Ma un&#39;insidia nel comportamento dei pazienti minaccia la crescita a lungo termine.

Farmaci anti-obesità: vendite da record, ma c&#39;è un problema

Siegen,,North,Rhine,Westphalia,,,Germany,-,10,11,2023:

Biotech

Large Cap

News

General

La Spagna indaga su presunte irregolarità nella promozione di farmaci dimagranti, con implicazioni per il settore e i consumatori.

La Spagna contro Novo Nordisk: pubblicità occulta per i farmaci dimagranti

Un&#39;importante azienda farmaceutica svela progressi su una nuova soluzione orale per la gestione del peso. Scopri di più.

Perdere peso senza sacrifici? Arriva la pillola orale di Eli Lilly

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 89 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 44% bearish. Among these notable options, 25 are puts, totaling $2,353,651, and 64 are calls, amounting to $51,869,753.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $500.0 to $1040.0 for Eli Lilly over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Eli Lilly stands at 1044.75, with a total volume reaching 30,575.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $500.0 to $1040.0, throughout the last 30 days.
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752264144_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$86.85</td>
<td>$86.25</td>
<td>$86.85</td>
<td>$790.00</td>
<td>$390.8K</td>
<td align="right">505</td>
<td align="right">101</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$86.0</td>
<td>$82.1</td>
<td>$86.0</td>
<td>$860.00</td>
<td>$387.0K</td>
<td align="right">82</td>
<td align="right">135</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$205.8</td>
<td>$203.5</td>
<td>$203.5</td>
<td>$580.00</td>
<td>$366.3K</td>
<td align="right">30</td>
<td align="right">18</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$82.55</td>
<td>$82.45</td>
<td>$82.45</td>
<td>$740.00</td>
<td>$197.7K</td>
<td align="right">133</td>
<td align="right">28</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$53.65</td>
<td>$52.4</td>
<td>$52.4</td>
<td>$790.00</td>
<td>$146.7K</td>
<td align="right">400</td>
<td align="right">69</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,047,296, the LLY's price is up by 0.2%, now at $792.27. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
<h3>What The Experts Say On Eli Lilly</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $1004.33.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Eli Lilly with a target price of $1135. 
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $942. 
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $936.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Market Whales and Their Recent Bets on LLY Options

In the latest quarter, 7 analysts provided ratings for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $952.29, with a high estimate of $1135.00 and a low estimate of $700.00. Observing a downward trend, the current average is 8.26% lower than the prior average price target of $1038.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1752242428_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$942.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1135.00</td>
<td>$1133.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$936.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1050.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Rajesh Kumar</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Reduce</td>
<td>$700.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$975.00</td>
<td>-</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$928.00</td>
<td>$973.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eli Lilly. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eli Lilly compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Eli Lilly's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Eli Lilly's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LLY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Eli Lilly analyst ratings.</a>
<h2>About Eli Lilly</h2>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, Eli Lilly showcased positive performance, achieving a revenue growth rate of 45.17% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 21.68%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Eli Lilly's ROE excels beyond industry benchmarks, reaching 18.42%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Eli Lilly's ROA stands out, surpassing industry averages. With an impressive ROA of 3.28%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.44, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts

Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and raises the price target from $936 to $942.

Price Target

Guggenheim Maintains Buy on Eli Lilly, Raises Price Target to $942

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to &#8220;benefit&#8221; from the levies. 
What Happened: Trump announced on Tuesday that the pharma tariffs, part of a Section 232 investigation launched in April, are expected to be detailed by month's end, with a grace period of "about a year, year and a half" before implementation.
Barclays cautioned that a 200% tariff would "inflate production costs, compress profit margins, and risk supply chain disruptions.&#8221; However, the delay offers little relief, <a href="https://www.cnbc.com/2025/07/11/trump-200percent-pharma-tariffs-threaten-to-push-up-drug-prices-hit-margins.html">as</a> CNBC reported, quoting UBS analysts that it's "insufficient time" for firms to relocate manufacturing, typically a four-to-five-year process. 
But despite the potential negative impact on pharma companies, Louis Navellier told <a href="https://www.benzinga.com">Benzinga </a>that Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is &#8220;expected to benefit from tariffs on pharmaceutical imports, since the company has been boosting its domestic manufacturing.&#8221;
Additionally, Thomas Shipp, head of equity research at LPL Financial, told <a href="https://pro.benzinga.com/dashboard">Benzinga</a> that Lilly's attempt to try &#8220;to avoid PBMs,&#8221; exemplified by its direct-to-consumer model, &#8216;LillyDirect&#8217; in partnership with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), positions it to bypass traditional pharmacy benefit managers, enhancing its resilience against tariff-related disruptions.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46361386/bitcoin-breaches-118k-but-these-btc-mining-firms-are-still-priced-like-its-at-58k-heres-how-these-mining-stocks-could-explode">Bitcoin Breaches $118K, But These BTC Mining Firms Are Still Priced Like It&#8217;s At $58K: Here&#8217;s How These Mining Stocks Could Explode</a>
Why It Matters: Additionally, Lilly's strategic moves, including a $1.3 billion <a href="https://www.benzinga.com/m-a/25/06/45970361/eli-lilly-expands-into-gene-editing-with-verve-therapeutics-acquisition">acquisition of Verve Therapeutics</a>, signal its focus on innovation and U.S.-based growth. 
Ark Research noted that this acquisition validates gene-editing therapies for cardiovascular disease, a market with "trillions of dollars" in potential, as Lilly scales solutions like PCSK9-targeting therapies that reduce LDL-C by up to 69%.
Apart from the effects on the profitability of pharmaceutical companies, according to PhRMA, the tariffs could raise U.S. drug prices by $51 billion annually with just a 25% tariff levy, potentially increasing costs by 12.9%.
Price Action: Eli Lilly stock declined 0.078% in premarket on Friday; it was up 1.62% on a year-to-date basis but down by 15.36% over the last year.
Benzinga Edge Stock Rankings shows that LLY had a weak momentum and value ranking; however, its growth and quality metrics were very strong. The details of all the important indicators are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="163" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png" alt="" class="wp-image-981662" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-300x48.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-768x122.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge.png 1039w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
These are some pharma stocks and ETFs that could be impacted as Trump warned on Tuesday that long-awaited industry-wide tariffs would be announced "very soon".
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>1.62%</td>
<td>-15.36%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>8.67%</td>
<td>14.77%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-14.56%</td>
<td>19.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-21.73%</td>
<td>-48.18%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.12%</td>
<td>-10.05%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>24.66%</td>
<td>63.70%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-15.28%</td>
<td>-34.85%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>15.85%</td>
<td>-7.60%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>9.49%</td>
<td>5.34%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>3.50%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>3.15%</td>
<td>-0.88%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>0.68%</td>
<td>-0.49%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-0.16%</td>
<td>2.31%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>25.74%</td>
<td>30.34%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-1.00%</td>
<td>-4.29%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-14.12%</td>
<td>-14.74%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46336115/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-sh">As Trump Calls For 3-Percentage Point Rate Cut, &#8216;Too Late&#8217; Jerome Powell To Resign, June Fed Minutes Show &#8216;Uncertainty&#8217; Reigns Supreme</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shuttertsock

Equities

ABBV

AMGN

AMZN

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

REGN

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight and raises the price target from $1133 to $1135.

Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1135

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 40 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 55% leaning bullish and 25% bearish. Among these notable options, 6 are puts, totaling $330,318, and 34 are calls, amounting to $5,397,011.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $370.0 to $990.0 for Eli Lilly over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 321.08 with a total volume of 4,088.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $370.0 to $990.0 over the last 30 days.
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752163269_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$169.0</td>
<td>$169.0</td>
<td>$169.0</td>
<td>$750.00</td>
<td>$1.6M</td>
<td align="right">617</td>
<td align="right">98</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$168.85</td>
<td>$167.0</td>
<td>$168.85</td>
<td>$750.00</td>
<td>$472.7K</td>
<td align="right">617</td>
<td align="right">164</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$168.85</td>
<td>$167.0</td>
<td>$168.85</td>
<td>$750.00</td>
<td>$320.8K</td>
<td align="right">617</td>
<td align="right">183</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$49.5</td>
<td>$49.15</td>
<td>$49.5</td>
<td>$830.00</td>
<td>$297.0K</td>
<td align="right">182</td>
<td align="right">102</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$169.0</td>
<td>$168.85</td>
<td>$169.0</td>
<td>$750.00</td>
<td>$287.3K</td>
<td align="right">617</td>
<td align="right">126</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>With a volume of 1,089,317, the price of LLY is up 1.15% at $795.98. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 28 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $936.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Guggenheim has revised its rating downward to Buy, adjusting the price target to $936. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Eli Lilly

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is set to release its second-quarter earnings on August 7. According to&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a> data,&nbsp;analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.
Expectations are slightly higher for the quarter, primarily driven by the strong performance of its obesity drug, Zepbound. The pharmaceutical giant, a dominant player in the incretin/GLP-1 drug market for obesity and diabetes, continues to draw investor attention with its robust pipeline and long-term growth prospects.
<h2 class="wp-block-heading">Analyst Adjustments and Forecasts</h2>
Ahead of the earnings release, Bank of America Securities (BofA) has made minor adjustments to its earnings model for Eli Lilly.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46319441/fda-approves-new-dosing-schedule-for-eli-lillys-kisunla-in-alzheimers-treatment" rel="noreferrer noopener">FDA Approves New Dosing Schedule For Eli Lilly&#8217;s Kisunla In Alzheimer&#8217;s Treatment</a>
BofA analyst Tim Anderson specifically noted a slight, low single-digit percentage increase in <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">second-quarter revenue</a> and EPS forecasts, primarily driven by stronger anticipated sales of Zepbound.
Looking further out, the analyst updated full-year projections, expecting total revenue to rise by 1% and 0.4% in 2025, with EPS growing by 1.9% in 2025 but experiencing a slight dip of 0.7% in 2026.
Beyond 2026, revenue and EPS projections largely remain consistent. Importantly, long-term forecasts for Lilly&#8217;s key products, Mounjaro, Zepbound, orforglipron, and retatrutide, have not seen significant revisions.
<h2 class="wp-block-heading">BofA Maintains Buy Rating</h2>
BofA maintains a Buy rating on Eli Lilly, with a <a target="_blank" href="https://www.benzinga.com/quote/LLY/analyst-ratings" rel="noreferrer noopener">price forecast of $1,000</a>. This reflects the firm&#8217;s view of Lilly&#8217;s exceptional and sustainable growth potential compared to its peers, at what is considered a reasonable valuation.
The core focus of the company remains its incretin/GLP-1 drugs for obesity and diabetes, a market where Lilly is expected to maintain a leading position in the foreseeable future alongside one other top company.
<h2 class="wp-block-heading">Key Focus Areas for the Earnings Call</h2>
The earnings call will focus on several key areas. Broader concerns around U.S. drug pricing changes, including the &#8216;most favored nation&#8217; proposal and possible pharma-related tariffs under Section 232, are expected to be discussed.
Important upcoming clinical trial results, such as tirzepatide&#8217;s SURPASS-CVOT, orforglipron&#8217;s ATTAIN-1, and Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) REDEFINE-4, will also be a point of interest.
Performance updates on major products, especially Mounjaro and Zepbound, will be closely watched. Additionally, early launch progress for new drugs like Kisunla for Alzheimer&#8217;s and Ebglyss for eczema will be highlighted.
Price Action: LLY stock is trading higher by 0.82% to $784.07 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46324159/why-china-automotive-systems-stock-is-gaining-on-wednesday" target="_blank" rel="noreferrer noopener">Why China Automotive Systems Stock Is Gaining On Wednesday</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Earnings

Guidance

Reiteration

Topics

Trading Ideas

Zepbound Powers Eli Lilly's Upbeat Q2 Outlook

The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Kisunla (donanemab-azbt) once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer&#8217;s disease (AD). The FDA approved the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39620867/eli-lillys-alzheimers-therapys-broad-label-reflects-regulatory-confidence-in-anti-a" target="_blank" rel="noreferrer noopener">drug in July 2024</a>.
In the <a href="https://www.benzinga.com/general/biotech/24/10/41608511/eli-lilly-says-new-data-can-potentially-provide-path-to-improved-donanemab-profile-by-lower-risk-" target="_blank" rel="noreferrer noopener">TRAILBLAZER-ALZ 6 study</a>, the modified titration schedule significantly reduced the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) compared to the original dosing schedule at 24 and 52 weeks, while still achieving similar levels of amyloid plaque removal <a href="https://www.benzinga.com/pressreleases/25/07/n46314838/fda-approves-updated-label-for-lillys-kisunla-donanemab-azbt-with-new-dosing-in-early-symptomatic-" target="_blank" rel="noreferrer noopener">and P-tau217 reduction</a>.
The new recommended dosing regimen involves a more gradual titration.
ARIA-E is a side effect of amyloid plaque-targeting therapies, including Kisunla. ARIA-E is usually asymptomatic, although serious and fatal events can occur.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding" rel="noreferrer noopener">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a>
The new dosing recommendation differs from the original dosing by shifting a single vial from the first dose to the third dose, delivering the same amount of Kisunla by week 24.
This resulted in lower rates of ARIA-E without compromising Kisunla&#8217;s ability to reduce amyloid plaque or its once-monthly dosing, with the potential for a limited-duration treatment based on amyloid plaque removal to minimal levels.
Key findings from the TRAILBLAZER-ALZ 6 study, which supports this label update, included:
<ul class="wp-block-list">
<li>The results showed that the incidence of ARIA-E was 14% in patients receiving the modified titration regimen compared with 24% for those receiving the original dosing regimen, representing a 41% lower relative risk.</li>
<li>At week 52, the incidence of ARIA-E was 16% in patients receiving the modified titration compared with 25% for those receiving the original dosing regimen, a 35% lower relative risk.</li>
<li>Including asymptomatic radiographic events at week 52, ARIA, ARIA-E, and ARIA-H were observed in 29%, 16%, and 25% of patients receiving the modified titration dosing.</li>
<li>ARIA-E and ARIA-H are different types of amyloid-related imaging abnormalities (ARIA). ARIA with edema is characterized as ARIA-E, and ARIA with hemosiderin deposition is characterized as ARIA-H.</li>
</ul>
Patients on the modified titration experienced a reduction of amyloid plaque and P-tau217 comparable to patients receiving the original dosing regimen.
At 24 weeks, amyloid plaque levels in patients on the modified titration of donanemab in TRAILBLAZER-ALZ 6 were reduced on average by 67% from baseline compared to 69% for patients on the original dosing regimen.
No new adverse reactions were identified in the study, although higher rates of hypersensitivity and infusion-related reactions were observed.
In March, the European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued an opinion that does not recommend Eli Lilly&#8217;s donanemab be granted marketing authorization in early symptomatic Alzheimer&#8217;s disease. Lilly will seek <a href="https://www.benzinga.com/25/03/44544761/european-drug-regulator-gives-thumbs-down-to-eli-lillys-alzheimers-drug-analyst-says-it-is-incremental-win-for-biogen" target="_blank" rel="noreferrer noopener">re-examination by CHMP</a>.
Price Action: LLY stock is up 0.30% at $780 during the premarket session at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/07/46317822/merck-strikes-10-billion-deal-for-verona-secures-first-in-class-copd-drug" target="_blank" rel="noreferrer noopener">Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug</a></li>
</ul>
Photo: Shutterstock

FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment

The FDA Approves Eli Lilly's Label Update With A New Recommended Titration Dosing Schedule For Kisunla (Donanemab-azbt), Once-monthly Amyloid-targeting Therapy For Adults With Early Symptomatic Alzheimer's Disease

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Tuesday announced that it has submitted an application to the European Medicines Agency (EMA) for approval of a new, higher <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">dose of its obesity treatment</a>, Wegovy (subcutaneous semaglutide 7.2 mg).
The submission is based on clinical data from the STEP UP and STEP UP T2D trials, investigating the efficacy and safety of semaglutide 7.2 mg in adults with obesity in STEP UP, and adults with obesity and type 2 diabetes in STEP UP T2D.
In the STEP UP trial, the <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916360" rel="noreferrer noopener">new</a> dose of Wegovy (semaglutide 7.2 mg) demonstrated a substantial average weight loss of 21% in people with obesity, with a third of participants losing 25% or more of their body weight compared with placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46269816/wegovy-zepbound-prices-drop-but-most-patients-still-cant-afford-long-term-use-coverage-is-not-the-same-as-access-says-expert" rel="noreferrer noopener">Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: ‘Coverage Is Not The Same As Access,' Says Expert</a>
Data also indicated that semaglutide 7.2 mg had a well-tolerated safety profile consistent with semaglutide 2.4 mg and the previous Novo Nordisk semaglutide trials.
Data from&nbsp;clinical trials&nbsp;also point to a slightly higher risk of developing the condition in people taking semaglutide compared with people taking a placebo (a dummy treatment).
In June, EMA's safety committee (PRAC) concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">cause vision loss</a>.
After reviewing all available data on NAION with semaglutide, including data from non-clinical studies,&nbsp;clinical trials, post-marketing surveillance and the medical literature,&nbsp;the committee concluded that NAION is a very rare side effect of semaglutide (meaning it may affect up to 1 in 10,000 <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45814068/novo-nordisks-wegovy-tied-to-increased-risk-of-rare-vision-loss-disorder-european-regulators-say" rel="noreferrer noopener">people taking semaglutide)</a>.
<h2 class="wp-block-heading">Wegovy Vs. Mounjaro</h2>
Novo Nordisk launched Wegovy (semaglutide) in <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46076029/novos-india-move-could-reshape-the-weight-loss-drug-war-with-eli-lilly" rel="noreferrer noopener">India in June to compete</a> with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
Novo Nordisk told Reuters that Wegovy is available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses. The first three will cost 4,336 rupees ($50.7), and the monthly cost will be 17,345 rupees ($201.4), similar to Eli Lilly's Mounjaro.
Some of Novo Nordisk's executives say the company allegedly ignored internal warnings that it was <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/07/46198535/novo-nordisk-ignored-internal-warnings-on-wegovy-launch-preparedness-report" rel="noreferrer noopener">unprepared to launch Wegovy</a>.
Wegovy, approved in the U.S. in mid-2021, marked a major advancement in obesity treatment and helped Novo generate $46 billion in net profit since then.
But the company has struggled to keep pace with Lilly's Zepbound, which has surpassed Wegovy in weekly new prescriptions this year.
Price Action: NVO stock is up 1.43% at $70.32 at the last check on Tuesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46295652/wolfspeed-stock-continues-to-surge-whats-driving-the-momentum" target="_blank" rel="noreferrer noopener">Wolfspeed Stock Continues To Surge: What's Driving The Momentum?</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Eurozone

Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval

WW International, Inc. (WeightWatchers) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) announced on Tuesday&nbsp;the successful completion of its strategic reorganization process.
WeightWatchers implemented a financial reorganization transaction in May to strengthen its financial position and increase investment flexibility. The company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45239193/weightwatchers-takes-strategic-action-to-eliminate-1-15-billion-of-debt-strengthening-financial-po" rel="noreferrer noopener">eliminated $1.15 billion in debt</a>.
With this improved financial foundation, the company is well equipped to execute its transformation plan, which includes innovating its digital and member experience and accelerating the expansion of <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">its telehealth business</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/45073094/weightwatchers-integrates-with-eli-lilly-to-expand-access-to-zepbound-stock-skyrockets-110" rel="noreferrer noopener">WeightWatchers Integrates With Eli Lilly To Expand Access To Zepbound, Stock Skyrockets 110%</a>
The company said in a press release in May that the business delivered 57% year-over-year revenue growth in the first quarter of 2025.
As part of this accelerated transformation, WeightWatchers made key leadership appointments. In its SEC <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/105319/000119312525156416/d83528dex991.htm" rel="noreferrer noopener">filing</a> on Tuesday, WeightWatchers said it appointed Dr.&nbsp;Kim Boyd as Chief Medical Officer to lead the company&#8217;s clinical vision, program development, and the integration of science into solutions for members.
&#8220;This is a pivotal moment for WeightWatchers,&#8221; said Tara Comonte, Chief Executive Officer of WeightWatchers. &#8220;With renewed financial strength, an expanded leadership team, and the addition of Dr.&nbsp;Boyd to lead clinical strategy and program innovation, we&#8217;re accelerating our transformation.&#8221;
Looking ahead, WeightWatchers will launch a new program later this year to support women through perimenopause, menopause, and postmenopause.
The offering builds upon WeightWatchers&#8217; existing program by delivering tailored nutritional and behavioral strategies with access to specialized clinical care, coaching, and community. The expansion into women&#8217;s health is a strategic move to address a broader gap in healthcare.
In addition to Dr. Boyd&#8217;s appointment, WeightWatchers has appointed Uta Knablein as Chief Product Officer to lead product strategy across the company&#8217;s expanding weight health platform.
As part of WeightWatchers&#8217; reorganization, a new Board of Directors will guide the company through its next growth phase.
Earlier in July, WeightWatchers announced an <a target="_blank" href="https://corporate.ww.com/news/news-details/2025/WeightWatchers-and-Novo-Nordisk-Expand-Collaboration-to-Improve-Medication-Access-Through-Trusted-Holistic-Model-of-Care/default.aspx" rel="noreferrer noopener">expanded</a> collaboration with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), which includes increased access to authentic, FDA-approved Wegovy (semaglutide) injection through WeightWatchers Clinic.
Additionally, Novo Nordisk is offering a limited-time savings offer available to WeightWatchers Clinic members. Starting July 1, 2025, eligible cash-pay members can access Wegovy at a reduced price of $299 until&nbsp;July 31, 2025.
In April, WeightWatchers announced a pharmacy integration with Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) LillyDirect <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45066438/weightwatchers-streamlines-member-access-to-zepbound-vials-with-lillydirect-pharmacy-provider" rel="noreferrer noopener">pharmacy provider</a>, Gifthealth.
The integration will streamline access to Lilly&#8217;s FDA-approved Zepbound (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician.
The integration will streamline access to Zepbound by offering a vial format for eligible Zepbound self-pay patients without insurance coverage.
Gifthealth will fulfill on-label prescriptions for Zepbound vials written by board-certified clinicians. WeightWatchers members will receive real-time Rx tracking directly within the WeightWatchers App.
Price Action: WW stock is trading higher by 2.75% to $41.10 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/07/46298240/voo-gets-some-love-as-investors-say-no-thanks-to-magnificent-7-stocks" target="_blank" rel="noreferrer noopener">VOO Gets Some Love As Investors Say &#8216;No Thanks&#8217; To Magnificent 7 Stocks</a></li>
</ul>
Photo by shisu_ka via Shutterstock

Movers

WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 10 years by 12.75% on an annualized basis producing an average annual return of 24.16%. Currently, Eli Lilly has a market capitalization of $693.38 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 10 years ago, it would be worth $8,701.53 today based on a price of $771.99 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751929214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its head above parity. Nevertheless, the statistical winds may point to an eventual recovery which options traders could potentially exploit.
Fundamentally, in the post-pandemic era, sentiment toward Eli Lilly skyrocketed thanks to its <a href="https://www.benzinga.com/news/25/01/42933134/fda-approves-weight-loss-drug-zepbound-for-sleep-apnea-will-insurance-cover-this-1000-per-month-medication">weight-loss drug</a>. In 2023, the U.S. Food and Drug Administration (FDA) approved the Zepbound (tirzepatide), the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. An injectable prescription medication that helps adults with other weight-related problems, Zepbound's clinical trials showed promising results.
Thanks to this early success, Eli Lilly and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) effectively formed a duopoly in the weight-loss market. While this reality contributed to a significant valuation surge, competition started to heat up last year. With major pharmaceuticals like Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Roche Holding Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announcing advancements in the <a href="https://www.benzinga.com/general/biotech/24/07/39849867/exclusive-weight-loss-duopoly-breaks-as-eli-lilly-novo-plummet-market-wont-be-dominated-by-just-2">development of obesity-fighting drugs</a>, LLY stock entered into a frustrating consolidation channel.
Still, with the pharmaceutical giant incurring an extended period of red ink in the market, JPMorgan analyst Chris Schott is essentially making the case that Eli Lilly is undervalued. Specifically, prescriptions for Zepbound and Mounjaro (an injectable <a href="https://www.lilly.com/news/media/media-kits/mounjaro">medicine</a> for adults with type 2 diabetes) are running ahead of expectations in the second quarter. As such, this performance may allow the pharmaceutical to beat and raise guidance throughout 2025.
Even with the <a href="https://www.benzinga.com/content/45261458/is-eli-lilly-a-buy-after-weak-earnings-and-cvs-novo-partnership">formulary change</a> by CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) putting around 200,000 patients at risk of losing access, Schott states that Eli Lilly's market share — which stands at about 70% to 75% of new patients — and strong momentum may help the company easily absorb the impact.
<h2 class="wp-block-heading">Statistical Backdrop Could Point To A Recovery In LLY Stock</h2>
Although the fundamental narrative of LLY stock is intriguing, it may also be a presuppositional leap. Essentially, the conclusion that LLY is undervalued is already embedded in the premise (that the market is not fully pricing in the good news for Eli Lilly).
If one thinks about it, it's an extraordinary claim. LLY stock routinely ranks among the most actively traded securities. That the market is somehow mispricing the pharmaceutical giant is an assertion that requires extraordinary evidence. In my opinion, if such evidence exists, it will likely materialize in the statistical realm as it's the arena that few (if any) analysts venture into.
A significant barrier to statistical analysis of the financial markets is the deployment of continuous scalar signals, such as share price or various valuation ratios. Because these signals are non-stationary, it's difficult (if not outright impossible) to extract meaningful insights based on the frequency of past analogs. Especially for highly traded securities like LLY stock, the measurement metrics constantly fluctuate.
To remedy this problem, we can impose stationarity by converting scalar signals into discrete states. For analyzing securities, converting share price into market breadth or sequences of accumulative and distributive sessions carries significant advantages. First, market breadth is essentially a representation of demand and demand is effectively binary. Second, clusters of binary codes can form distinct behavioral states, which can then serve as past analogs for extracting forward probabilities.
As an example, in the trailing two months, the price action of LLY stock can be interpreted as a "6-4-D" sequence: six up weeks, four down weeks, with a negative trajectory across the 10-week period. Admittedly, this process pancakes LLY's magnitude dynamism into a simple binary code. But the benefit is that this code can be easily segregated into distinct market profiles. From there, we can observe the likelihood of transition from one state to another.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-975331" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
With the above framework, we can identify that since January 2019, the 6-4-D sequence has materialized 38 times. From past analogs, we can also determine that in 68.42% of cases, the following week's price action results in upside, with a median return of 2.47%.
Accounting for the volatility on Monday, a realistic target over the next three weeks — assuming that the bulls gain and maintain control of the market — is just under the $800 level.
<h2 class="wp-block-heading">Playing The Odds With Eli Lilly</h2>
Based on the market intelligence above, bold speculators may consider the 785/790 bull call spread expiring Aug. 1. This transaction involves buying the $785 call and simultaneously selling the $790 call, for a net debit paid of $255 (the most that can be lost in the trade). Should LLY stock rise through the short strike price ($790) at expiration, the maximum reward is $245, a payout of 96%.
To be sure, the 780/790 bull spread expiring on the same day offers a payout of nearly 113%. However, the net debit required is $470, which puts significantly more capital at risk for only a modest increase in payout. Therefore, the 785/790 call spread is arguably more tempting.
Either way, both transactions require LLY stock to hit or exceed $790 on Aug. 1, which empirically appears to be a reasonable target. As a baseline, the chance that a long position in LLY will be profitable on any given week is quite high at 60.29%. However, the market's response to the 6-4-D sequence amplifies the odds in favor of the bullish speculator, thus incentivizing a debit-based strategy.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46253955/khc-stock-bearish-pressure-statistical-reversal">Options Corner: Why Kraft Heinz Could Flip The Script On The Bears</a></li>
</ul>
Photo: Shutterstock

Long Ideas

RHHBY

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) is currently experiencing a decline in its stock price, trading lower on Monday. The company&#8217;s stock has plummeted approximately 18% over the past month, reflecting recent challenges.
A significant development contributing to this decline occurred in June 2025, when Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) ended its collaboration with Hims &amp; Hers. Consequently, Hims &amp; Hers will no longer have direct access to Wegovy, Novo Nordisk&#8217;s popular GLP-1 weight-loss drug, through the <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46050799/hims-hers-health-stock-is-tumbling-monday-whats-happening" rel="noreferrer noopener">NovoCare Pharmacy</a>.
Novo Nordisk stated in a press release that the termination was due to Hims &amp; Hers Health&#8217;s alleged failure to adhere to laws prohibiting mass sales of compounded drugs under the false guise of &#8220;personalization&#8221; and its use of deceptive marketing practices, which Novo Nordisk claimed disregarded patient safety.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46269816/wegovy-zepbound-prices-drop-but-most-patients-still-cant-afford-long-term-use-coverage-is-not-the-same-as-access-says-expert" rel="noreferrer noopener">Wegovy, Zepbound Prices Drop, But Most Patients Still Can&#8217;t Afford Long-Term Use: &#8216;Coverage Is Not The Same As Access,&#8217; Says Expert</a>
This split represents the latest challenge facing Hims &amp; Hers, even as the company aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030.
Hims &amp; Hers Health shares are under pressure largely because the firm sells cheaper, compounded versions of popular weight-loss drugs. Regulators typically permit compounded versions of drugs to enter the market to meet demand when there&#8217;s an official shortage of the brand-name product.
However, the FDA announced earlier this year that semaglutide, the active ingredient in Wegovy, had been removed from the drug shortage list, indicating that supply was now sufficient to meet current and projected demand. This change had a notable impact on Hims &amp; Hers.
Despite this, the company reported significant success in its GLP-1 offerings, generating over <a target="_blank" href="https://www.benzinga.com/25/05/45567780/hims-hers-health-stock-is-tumbling-thursday-whats-happening" rel="noreferrer noopener">$225 million in revenue</a> in 2024 from these products. The ongoing legal and regulatory scrutiny now centers on the legality of mass-producing compounded versions once the official shortage is declared over.
Morgan Stanley, in a Monday note, highlighted an &#8220;increased focus on both the legal and business implications that could influence the stock.&#8221; Analysts spoke with two experts to gain insight into these implications, particularly concerning Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42783449/eli-lilly-joins-fda-lawsuit-over-compounded-obesity-drugs-seeks-swift-end-and-to-protect-its-interests" rel="noreferrer noopener">lawsuits against compounders</a>.
Analyst Craig Hettenbach says that Expert #1 cautiously advised compounding pharmacies to cease large-scale production of GLP-1 drugs once the shortage ends, acknowledging that business owners have varying levels of risk tolerance.
Expert #2 offered a more nuanced perspective, suggesting there might be a legitimate case for compounding GLP-1s under 503A for specific patient groups, even if the drugs are not individually tailored. Nevertheless, Expert #2 admitted that little legal precedent supports this view and believed that merely adding a vitamin to a GLP-1 would likely not render the product legally compliant under 503A, a common practice among some compounders.
Both experts indicated that even if the current cases are dismissed, Eli Lilly could refile with stronger arguments. Presently, the compounders are seeking dismissal of the lawsuits, contending that Eli Lilly, as a private company, cannot make certain claims that fall solely under the FDA&#8217;s jurisdiction.
The two experts discussed whether it would be helpful to ask for a preliminary injunction, a court order to stop the compounders from operating during the case. Expert #2 thinks it will be hard for Lilly to get one because the company would need to prove it&#8217;s suffering serious, irreversible harm.
Without that injunction, the compounders can keep running their businesses while the cases are ongoing. Both experts stressed that each case depends heavily on the specific facts, so gathering evidence and going through the legal process will take time. A final decision in these cases will probably take 2 to 3 years.
In light of these developments, Morgan Stanley has maintained its Equal Weight rating on Hims &amp; Hers Health, with <a target="_blank" href="https://www.benzinga.com/quote/HIMS/analyst-ratings" rel="noreferrer noopener">a price forecast of $40</a>.
Earlier in June, the company announced a significant step in its global expansion through its agreement to acquire ZAVA, a <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45779301/hims-hers-zava-acquisition-deal-expands-its-market-opportunity-by-52-billion-analyst" rel="noreferrer noopener">digital health platform in Europe</a>.
The strategic move will expand Hims &amp; Hers&#8217; footprint in the United Kingdom and officially launch the company into Germany, France, and Ireland, with more markets anticipated soon.
Price Action: HIMS stock is trading lower by 5.51% to $45.38 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/guidance/25/07/46273556/molina-healthcare-says-higher-medical-cost-trends-bite-cuts-profit-guidance" target="_blank" rel="noreferrer noopener">Molina Healthcare Says Higher Medical Cost Trends Bite, Cuts Profit Guidance</a></li>
</ul>
Image by T. Schneider via Shutterstock

Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access despite strong market demand.
What Happened: The medications cost around $500 monthly for uninsured patients, while insured coverage remains inconsistent across plans. &#8220;Coverage is not the same as access,&#8221; said Beverly Tchang, a New York-based physician who advises both Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), reported <a href="https://apnews.com/article/wegovy-zepbound-obesity-drugs-coverage-access-142e234c16df4443e8f66c27d01f44e2#">the</a> Associated Press.
GLP-1 receptor agonists continue driving substantial revenue for both drugmakers. Zepbound generated $2.3 billion in U.S. first-quarter sales, while Wegovy contributed nearly $1.9 billion with approximately 200,000 weekly prescriptions domestically.
Insurance coverage varies dramatically by provider and plan type. Novo Nordisk reports that 85% of covered U.S. patients pay $25 or less monthly. However, most state Medicaid programs and Medicare exclude obesity coverage, forcing patients to shoulder hundreds in out-of-pocket costs monthly, according to the report.
See Also: <a href="https://www.benzinga.com/markets/large-cap/25/07/46269182/ai-assistants-could-break-amazons-60-billion-retail-media-business-warns-vc-its-not-just-search-at-google-its-search-everywhere">AI Assistants Could Break Amazon&#8217;s $60 Billion Retail Media Business, Warns VC: &#8216;It&#8217;s Not Just Search At Google — It&#8217;s Search Everywhere&#8217;</a>
Why It Matters: The regulatory landscape remains complex regarding compounded versions. Despite FDA determinations that drug shortages ended, compounding pharmacies continue selling cheaper alternatives under personalization exceptions.
Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) offers compounded semaglutide starting at $165 monthly, leading to legal challenges from Eli Lilly.
Recent pricing trends show that both companies reduced uninsured patient costs by several hundred dollars from initial launch prices. However, $500 monthly represents approximately 14% of the average U.S. per-capita income at $43,000 annually.
Long-term adherence data reveals persistence challenges that could impact market expansion. Real-world studies show only 8.1% of patients maintained GLP-1 obesity therapy after three years, though one-year persistence for Wegovy <a href="https://www.benzinga.com/news/health-care/25/06/46102213/us-adults-struggle-with-long-term-use-of-obesity-drugs-like-wegovy-data-shows">improved from 33.2% in 2021 to 62.7% in 2024</a>.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46268630/alphabet-backed-drug-discovery-firm-nears-human-trials-of-ai-developed-remedies-says-president-the-next-big-milestone-is">Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: &#8216;The Next Big Milestone Is…&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Tobias Arhelger / Shutterstock.com

Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert

Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Isomorphic Labs says its first artificial-intelligence-designed medicines are nearly ready for human testing.
What Happened: Isomorphic Labs President Colin Murdoch <a href="https://fortune.com/2025/07/06/deepmind-isomorphic-labs-cure-all-diseases-ai-now-first-human-trials/">spoke</a> to Fortune in an interview recently where he said, &#8220;There are people sitting in our office in King's Cross, London, collaborating with AI to design drugs for cancer right now.&#8221;
"The next big milestone is actually going out to clinical trials, starting to put these things into human beings," Murdoch added. "We're staffing up now. We're getting very close." Isomorphic, spun out of Google DeepMind in 2021, grew from AlphaFold, the program that predicts protein shapes with near-lab accuracy.
Murdoch said AlphaFold's latest version can simulate how candidate compounds bind to DNA and proteins, letting chemists iterate faster and more precisely. In 2024, Isomorphic <a href="https://www.benzinga.com/news/24/01/36528778/googles-ai-spin-off-isomorphic-labs-strikes-big-pharma-deals-paving-the-way-for-future-of-drug-disco">struck research pacts</a> with Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and, in April this year, raised $600 million led by Thrive Capital to build what Murdoch calls a "world-class drug design engine."
See also: <a href="https://www.benzinga.com/markets/tech/25/07/46268414/as-elon-musks-rift-with-donald-trump-deepens-former-google-executive-says-maga-and-tech-world-cant-thrive-without-each-other">As Elon Musk&#8217;s Rift With Donald Trump Deepens, Former Google Executive Says MAGA And Tech World Can&#8217;t Thrive Without Each Other</a>
"We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful," he said.
Why It Matters: Rivals are rushing to the clinic as well. Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) expects seven programs to begin or read out human studies next year. On the other hand, Hong Kong-based Insilico Medicine earlier this year announced positive takeaways from <a href="https://www.clinicaltrialsarena.com/news/insilico-announces-positive-results-from-phase-i-trials-of-ai-designed-ism5411/?cf-view">trials</a> of its AI-designed drug meant for the treatment of inflammatory bowel disease (IBD).
Investor interest is surging. Recursion shares <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45822228/recursion-pharmaceuticals-stock-surges-on-breakthrough-ai-model-launch-with-mit">jumped</a> 18% last month after unveiling an open-source binding-prediction model developed with MIT. Chipmakers are piling in, too. AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) just <a href="https://www.benzinga.com/25/01/42874399/amd-invests-20m-in-absci-to-boost-ai-drug-discovery">invested $20 million</a> in Absci to challenge Nvidia's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/markets/large-cap/25/06/45910197/nvidia-just-partnered-with-a-weight-loss-giant-but-its-not-about-pills">BioNeMo platform</a> in AI drug discovery.
Alphabet shares score high on Quality and Growth in Benzinga's Edge Stock Rankings and has a favorable price trend in the short, medium and long term. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Check&nbsp;here&nbsp;for deeper insights into the stock</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="152" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07032034/goog-edge-1024x152.png" alt="" class="wp-image-974192" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07032034/goog-edge-1024x152.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07032034/goog-edge-300x45.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07032034/goog-edge-768x114.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07032034/goog-edge.png 1386w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Photo Courtesy: JHVEPhoto on Shutterstock.com
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46268015/indian-billionaire-mukesh-ambanis-50-50-joint-venture-with-larry-finks-blackrock-raises-2-1-billion-in-debut-fund-offering">Indian Billionaire Mukesh Ambani&#8217;s 50-50 Joint Venture With Larry Fink&#8217;s BlackRock Raises $2.1 Billion In Debut Fund Offering</a></li>
</ul>

GOOG

GOOGL

NVDA

RXRX

Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is…'

President Donald Trump&#8216;s $3.3 trillion domestic agenda bill, passed by House Republicans on Thursday, includes a significant but little-noticed victory for pharmaceutical companies that will cost taxpayers nearly $5 billion over the next decade.
What Happened: The legislation expands exemptions from Medicare&#8217;s drug price negotiation program, allowing manufacturers to keep prices higher for medications treating multiple rare diseases, The New York Times <a href="https://www.nytimes.com/2025/07/03/health/trump-bill-medicare-drug-prices.html">reported</a>. The Congressional Budget Office estimates this change will reduce government savings by $5 billion through 2034.
&#8220;This is essentially giving $5 billion back to the pharmaceutical industry,&#8221; said Benjamin Rome, a health policy researcher at Brigham and Women&#8217;s Hospital in Boston, according to the report. &#8220;It&#8217;s done in a way that is designed, on its face, to solve the problem of some misaligned incentives, but I don&#8217;t think it solves those problems.&#8221;
Under current law, costly drugs are exempt from Medicare price negotiations if they treat a single rare disease affecting fewer than 200,000 Americans. Drugmakers complained this policy discouraged them from seeking approval for additional rare disease treatments.
See Also: <a href="https://www.benzinga.com/news/politics/25/07/46257635/trump-administrations-ice-raids-compared-with-wwii-japanese-internment-camps-by-george-takei-politicians-lie-and-people-believe-that-lie">Trump Administration&#8217;s ICE Raids Compared With WWII Japanese Internment Camps By George Takei: &#8216;Politicians Lie, And People Believe That Lie&#8217;</a>
Why It Matters: This marks the most significant change to the Medicare negotiation program since Democrats created it in 2022, according to the report. 
The exemptions will apply to the third negotiation round affecting prices starting in 2028. Several drugs currently facing price cuts would have been spared under the new rules, including Imbruvica and Pomalyst for rare cancers.
The bill passed largely along party lines as part of Trump&#8217;s <a href="https://www.benzinga.com/news/politics/25/07/46255065/trumps-3-3-trillion-bill-passes-will-vulnerable-americans-pay-the-price">broader legislative package that includes tax cuts</a>, defense spending increases, and significant reductions to federal safety net programs. Democrats criticized the measure as favoring wealthy interests while burdening vulnerable Americans.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46258444/cognition-therapeutics-shares-jump-12-after-hours-following-encouraging-phase-2-alzheimers-trial-data">Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer&#8217;s Trial Data</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Maxim Elramsisy / Shutterstock.com

Politics

Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report

Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) executives allegedly ignored internal warnings that the company was unprepared to launch its <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">obesity drug Wegovy</a>.
As rival Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound gains momentum, the Danish pharmaceutical giant is grappling with the fallout of those early decisions.
Wegovy, approved in the U.S. in mid-2021, marked a major advancement in obesity treatment and helped Novo generate $46 billion in net profit since then.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46139132/spain-accuses-novo-nordisk-of-covert-advertising-for-prescription-weight-loss-drugs" rel="noreferrer noopener">Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs</a>
But the company has struggled to keep pace with Lilly&#8217;s Zepbound, which has surpassed Wegovy in weekly new prescriptions this year.
Amid concerns over its competitiveness in the weight-loss market, Novo is undergoing a leadership shake-up, including <a target="_blank" href="https://www.benzinga.com/news/management/25/05/45466201/ozempic-maker-novo-nordisk-looks-for-new-chief-jorgensen-steps-down" rel="noreferrer noopener">the recent dismissal</a> of CEO Lars Fruergaard Jorgensen and earlier departures like U.S. chief Doug Langa.
Sources told Reuters that during tense internal meetings, sales and marketing staff warned Langa about launching Wegovy too quickly after FDA approval.
They urged a delay until supply and insurance coverage were more secure. With a <a target="_blank" href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" rel="noreferrer noopener">list price of up to $1,300 per month</a>, many patients found the drug unaffordable without insurance, and Novo missed an opportunity to build a more stable launch pad while Lilly&#8217;s market entry was still years away.
However, company leadership in Copenhagen held to conservative sales expectations through 2025, Reuters report highlighted, underestimating the scale of demand driven by the global obesity epidemic. Former employees said Novo had internal indicators pointing to stronger uptake but failed to adjust its strategy accordingly.
The consequences were swift. Wegovy&#8217;s launch was plagued by supply shortages, leaving patients without doses and discouraging new users. The high cost also pushed some patients toward the gray market of compounded drugs.
Novo further faced criticism for pricing Wegovy significantly higher than its diabetes drug Ozempic, while Lilly entered the market with Zepbound at $1,080 and provided steep discounts through its LillyDirect pharmacy.
One former insider claimed that Novo hesitated to offer competitive rebates to pharmacy benefit managers (PBMs), limiting the drug&#8217;s accessibility.
This reluctance hurt relationships with insurers and failed to secure broader coverage, placing Novo at a disadvantage compared to Lilly&#8217;s aggressive pricing and reimbursement strategies.
Recently, Novo Nordisk launched its weight-loss drug Wegovy (semaglutide) in India to <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46076029/novos-india-move-could-reshape-the-weight-loss-drug-war-with-eli-lilly" rel="noreferrer noopener">compete with Eli Lilly</a>.
Price Action: NVO stock is trading higher by 0.13% to 69.11 at last check Tuesday.
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/07/46192989/mesoblast-targets-accelerated-fda-approval-for-heart-failure-drug-revascor" target="_blank" rel="noreferrer noopener">Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Media

Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report

Against a backdrop of regulatory scrutiny, with Spain investigating Novo Nordisk for alleged covert advertising of its popular weight-loss drugs, the U.K. is initiating research to determine if genetic factors impact the risk of acute pancreatitis associated with GLP-1 injections.
Yellow Card Biobank, a collaboration between the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England, will start investigating whether the risk of acute pancreatitis (inflamed pancreas) from GLP-1 injections for <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">weight loss and Type 2 diabetes</a> may be influenced by an individual&#8217;s genes.
The agency <a target="_blank" href="https://www.gov.uk/government/news/if-you-take-a-glp-1-medicine-and-have-been-hospitalised-by-acute-pancreatitis-the-yellow-card-biobank-wants-to-hear-from-you" rel="noreferrer noopener">said</a> in a statement on Thursday that although infrequent, acute pancreatitis has been reported with GLP-1 medicines.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46102213/us-adults-struggle-with-long-term-use-of-obesity-drugs-like-wegovy-data-shows" rel="noreferrer noopener">US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows</a>
Patients hospitalized with <a href="https://www.benzinga.com/general/biotech/23/10/35123873/novo-nordisks-weight-loss-drugs-like-wegovy-ozempic-may-pose-serious-stomach-risks-study-suggests" target="_blank" rel="noreferrer noopener">acute pancreatitis suspected </a>to be related to glucagon-like peptide-1 receptor agonists (GLP-1 medicines), such as Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic (semaglutide) and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro (Tirzepatide), are asked to report it to the MHRA&#8217;s&nbsp;Yellow Card scheme.
These medicines are sometimes referred to colloquially as &#8220;skinny jabs,&#8221; although they are licensed for both weight loss and Type 2 diabetes.&nbsp;
Healthcare professionals are also being asked to help recruit for the study by reporting Yellow Cards on behalf of patients experiencing acute pancreatitis while taking GLP-1 medicines.&nbsp;
When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to participate in the Biobank study.
This would involve providing further information and submitting a saliva or spit sample, which will be used to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genetic makeup.
Dr Alison Cave, MHRA Chief Safety Officer, said, &#8220;Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing. It is predicted that adverse drug reactions cost the NHS more than 2.2 billion pounds ($3.02 billion) a year in hospital stays alone.&#8221;
On June 19, Spain&#8217;s Ministry of Health, through the General Directorate of the Common Portfolio of Services of the National Health System (NHS) and Pharmacy, requested information from Novo Nordisk Pharma after detecting indications that one of its information portals may be <a href="https://www.bmj.com/content/389/bmj.r1319" target="_blank" rel="noreferrer noopener">violating</a> regulations regarding drug advertising.
The initiative follows a media report <a target="_blank" href="https://www.sanidad.gob.es/en/gabinete/notasPrensa.do?id=6699" rel="noreferrer noopener">about</a> a website, which redirects to another page called &#8220;Obesity without filters,&#8221; managed by the laboratory. It presents informative content related to the approach to obesity, including images expressly indicating that this is a Novo Nordisk initiative endorsed by various scientific societies.
The Ministry has formally requested that the company provide documentation regarding the endorsement declared by these scientific and professional organizations.
It has also drawn attention to another link on the website containing recommended questions for the doctor. Although no pharmacological treatment is explicitly mentioned, the Ministry believes that the content could constitute indirect advertising for prescription drugs, the public promotion of which is prohibited under current legislation.
Meanwhile, Novo Nordisk continues the expansion of patient access to Wegovy (semaglutide) injection 2.4 mg through a new collaboration with WeightWatchers beginning&nbsp;July 1, 2025.
WeightWatchers&nbsp;will <a target="_blank" href="https://www.prnewswire.com/news-releases/novo-nordisk-continues-efforts-to-support-patient-access-to-authentic-fda-approved-wegovy-and-prioritize-patient-safety-302492419.html" rel="noreferrer noopener">work</a> with&nbsp;CenterWell&nbsp;Pharmacy as the dispensing pharmacy managing prescription fulfillment and delivery for NovoCare Pharmacy.
Novo Nordisk said on Thursday that it is also introducing a new cash-offer price of&nbsp;$299, available through&nbsp;July 31, 2025.
This&nbsp;$299&nbsp;introductory price is available for self-paying patients new to the Wegovy&nbsp;savings offer or those who have not previously filled a prescription through NovoCare&nbsp;Pharmacy.
This builds on the previous&nbsp;$199&nbsp;Wegovy&nbsp;cash-offer patient price that expires on&nbsp;June 30, 2025.
Patients who redeemed the&nbsp;$199&nbsp;Wegovy&nbsp;savings offer&nbsp;between May 22 and June 30, 2025, will be eligible for the&nbsp;$299&nbsp;price on one fill&nbsp;between July 1 and July 31.
For subsequent months, self-paying patients will pay&nbsp;$499&nbsp;per month.
The company said in a press release that with all doses of FDA-approved Wegovy fully available nationwide, it is illegal under <a target="_blank" href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" rel="noreferrer noopener">U.S. compounding laws</a> to make or sell knockoff &#8220;semaglutide&#8221; drugs, with rare exceptions.&nbsp;
Price Action: NVO stock is up 1.77% at $68.90 during the premarket session at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46136734/rfk-jrs-cdc-panel-recommends-mercks-rsv-shot-for-infants" target="_blank" rel="noreferrer noopener">RFK Jr&#8217;s CDC Panel Recommends Merck&#8217;s RSV Shot For Infants</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs

<a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-updated-label-lillys-amyvid-florbetapir-f-18" title="https://investor.lilly.com/news-releases/news-release-details/fda-approves-updated-label-lillys-amyvid-florbetapir-f-18">https://investor.lilly.com/news-releases/news-release-details/fda-approves-updated-label-lillys-amyvid-florbetapir-f-18</a>

Ely Lilly Announces The U.S. FDA Approves Updated Label For Its Amyvid To Support Diagnosis Of Alzheimer's Disease In Patients

Press Releases

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Dividends

Lilly declares third-quarter 2025 dividend

Small Cap

Opinion

New AI Rollouts Signal Shift From Hype to Healthcare Reality

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease

AVAI

PLTR

VERV

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Guggenheim

Morgan Stanley

HSBC

Cantor Fitzgerald

Screenshot 2025-07-08 at 5.24.00 PM

ADBE

SBC Medical Group In Growth Mode: Company Gets Added To The Russell 3000 Index, Names New Chief Marketing Officer

Untitled design - 2025-03-31T165341.547

TNXP

VRTX

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2025-02-24 at 11.35.34 PM

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2024-11-20 at 6.30.30 PM

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Comments

Eli Lilly

Notizie

Ultime notizie per Eli Lilly (NYSE:LLY) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO